Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms- |
Target |
Action modulators, enhancers |
Mechanism GRPR modulators(Gastrin releasing peptide receptor modulators), αvβ3 modulators(Integrin alpha-V/beta-3 modulators), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lung Cancer | Phase 1 | China | 03 Sep 2022 | |
Brain Cancer | Phase 1 | China | 16 Aug 2022 | |
Breast Cancer | Phase 1 | China | 16 Aug 2022 | |
GRPR-positive tumors | Phase 1 | China | 16 Aug 2022 | |
Prostatic Cancer | Phase 1 | China | 16 Aug 2022 |